SCLX

Scilex Holding Company

SCLX, USA

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is headquartered in Palo Alto, California.

https://www.scilexholding.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SCLX
stock
SCLX

Is SCLX a good long term investment - Stock Rotation Strategies & Interactive Charts for Smarter Trading earlytimes.in

Read more →
SCLX
stock
SCLX

Datavault AI (NASDAQ: DVLT) Sets Dec. 24 Distribution Date for Dream Bowl 2026 Meme Coin The Globe and Mail

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$490.0005

Analyst Picks

Strong Buy

1

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-1.09

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

145.38 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-93.24 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

75.09 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 14.20% of the total shares of Scilex Holding Company

1.

Vanguard Group Inc

(4.2313%)

since

2025/06/30

2.

Vanguard Total Stock Mkt Idx Inv

(2.2848%)

since

2025/07/31

3.

BlackRock Inc

(1.9025%)

since

2025/06/30

4.

Geode Capital Management, LLC

(0.889%)

since

2025/06/30

5.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7161%)

since

2025/07/31

6.

Vanguard Balanced Index Inv

(0.6374%)

since

2025/07/31

7.

Fidelity Extended Market Index

(0.351%)

since

2025/07/31

8.

UBS Group AG

(0.2649%)

since

2025/06/30

9.

Morgan Stanley - Brokerage Accounts

(0.2596%)

since

2025/06/30

10.

Rafferty Asset Management, LLC

(0.2547%)

since

2025/06/30

11.

NORGES BANK

(0.1962%)

since

2025/06/30

12.

Quantinno Capital Management LP

(0.1936%)

since

2025/06/30

13.

Citadel Advisors Llc

(0.182%)

since

2025/06/30

14.

BlackRock Advantage Small Cap Core Instl

(0.1767%)

since

2025/07/31

15.

iShares Micro-Cap ETF

(0.1756%)

since

2025/08/31

16.

State Street Corp

(0.1709%)

since

2025/06/30

17.

Extended Equity Market Fund K

(0.1497%)

since

2025/06/30

18.

Bank of America Corp

(0.1381%)

since

2025/06/30

19.

Fidelity Total Market Index

(0.123%)

since

2025/07/31

20.

Belfund SICAV Belinvest Equity A USD Acc

(0.1147%)

since

2025/07/31

21.

T. Rowe Price Extended Equity Market Idx

(0.1035%)

since

2025/07/31

22.

Fidelity Series Total Market Index

(0.0875%)

since

2025/07/31

23.

Barclays PLC

(0.0803%)

since

2025/06/30

24.

Spartan Extended Market Index Pool F

(0.0769%)

since

2025/07/31

25.

Northern Trust Extended Eq Market Idx

(0.0739%)

since

2025/06/30

26.

NT Ext Equity Mkt Idx Fd - L

(0.0739%)

since

2025/06/30

27.

NT Ext Equity Mkt Idx Fd - NL

(0.0606%)

since

2025/06/30

28.

Fidelity Small Cap Index

(0.0597%)

since

2025/06/30

29.

NT Col R2000 Val Idx Fd -DC -L -TierFour

(0.0434%)

since

2025/03/31

30.

BNP Paribas Arbitrage, SA

(0.0369%)

since

2025/06/30

31.

State Street Russell 2000 Value CIT

(0.0189%)

since

2025/03/31

32.

MetLife Investment Management, LLC

(0.0157%)

since

2025/06/30

33.

Royal Bank of Canada

(0.0132%)

since

2025/06/30

34.

Deutsche Bank AG

(0.0115%)

since

2025/06/30

35.

Versant Capital Management Inc

(0.0109%)

since

2025/06/30

36.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0107%)

since

2024/12/31

37.

Activest Wealth Management

(0.0043%)

since

2025/06/30

38.

SSgA U.S. Total Market Index Strategy

(0.004%)

since

2025/03/31

39.

Wells Fargo & Co

(0.0037%)

since

2025/06/30

40.

Van Eck Associates Corporation

(0.0007%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-22.17

EPS Estimate

-0.12

EPS Difference

-22.05

Surprise Percent

-18375%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(8.3)
GARP
Fair GARP(4.5)
Growth
Moderate Growth(4.5)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Moderate Quality(4.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.